| Literature DB >> 31850255 |
Marat Imashev1, Alexandr Fursov1, Bagdat Imasheva1, Roman Fursov1, Yerzhan Kuspaev1, Timofei Kovalenko1, Alishan Ismailov1, Aigul Abduldayeva1, Irina Volchkova1.
Abstract
BACKGROUND: The prevalence of bleeding and perforation against the diabetes mellitus, obesity and metabolic syndrome (MetS) is studied not sufficiently.Entities:
Keywords: Diabetes mellitus; Gastroduodenal bleeding; Metabolic syndrome
Year: 2019 PMID: 31850255 PMCID: PMC6908906
Source DB: PubMed Journal: Iran J Public Health ISSN: 2251-6085 Impact factor: 1.429
Morbidity of Peptic Ulcer Disease, Diabetes, Obesity and Metabolic Syndrome in Kazakhstan
| Astana | 91.2 (2.0) | 108.7 (2.1) | 1.3 | 150.3 (2.2) | 178.8 (2.1) | 1.3 | 87.3/23.9 (1.1) | 109.1/37.5 (1.0) | 1.7/3.8 |
| Urban population of Kazakhstan | 80,3 (2.1) | 106,2 (2.0) | 2.2 | 188.5 (2.1) | 236.2 (2.2) | 1.7 | 78.4/ 22.1 (1.1) | 96.9/ 36.7 (1.0) | 1.6/ 4.4 |
| Women | 35.2 (1.1) | 48.0 (1.1) | 2.4 | 185.5 (2.1) | 273.1 (2.2) | 3.1 | 112.3/ 35.5 (1.1) | 138.5/ 63.2 (1.1) | 1.6/ 5.9 |
| Men | 147.2 (2.1) | 169.4 (2.0) | 1.0 | 115.1 (2.2) | 84.5 (2.2) | −1.8 | 89.5/ 23.0 (2.2) | 95.3/ 30.3 (2.2) | 0.4/ 2.1 |
| Patients 18 yr and older | 81.1 (2.2) | 112.2 (2.2) | 2.6 | 200.5 (2.2) | 327.3 (2.2) | 4.2 | 225.9/ 56.0 (2.2) | 253.1/ 78.2 (2.2) | 0.8/ 2.6 |
| Patients 15–17 yrold | 8.3 (0.01) | 10.3 (0.01) | 1.6 | 11.5 (0.01) | 16.8 (0.01) | 3.1 | 12.9/ 3.0 (0.01) | 15.8/ 3.1 (0.01) | 1.5/ 0.2 |
| M | 99.0 (2.2) | 101.0 (2.2) | 0.1 | 126.1 (2.2) | 201.4 (2.2) | 4.0 | 73.8/ 23.1 (2.2) | 92.2/ 33.8 (2.2) | 1.7/ 3.1 |
- number of diseases SD, registered for the first time, per 100 000 people of the population with a confidential interval of 95% and a statistical significance level, P≤0.05;
(…) – SD; MetS - Metabolic Syndrome; R…% - the annual increase: Ru – ulcer;
Rd - diabetes; Ro – obesity; Rms - metabolic syndrome; M - the average for country
The number of admitted and hospitalized patients with surgical gastroduodenal complications with obesity and diabetes*
| 2003 | 501998 | 81.275 | 39.841 | 40.040 | 3.22/0.81 | 43.426 | 6.51/1.76 |
| 2004 | 510533 | 82.659 | 41.329 | 42.700 | 3.01/0.76 | 42.7 | 6.6/1.72 |
| 2005 | 529335 | 86.901 | 36.461 | 45.718 | 3.01/0.76 | 45.718 | 6.69/1.74 |
| 2006 | 550438 | 87.203 | 36.335 | 44.510 | 2.88/0.73 | 43.602 | 6.59/1.73 |
| 2007 | 574448 | 89.651 | 38.820 | 43.868 | 2.76/0.70 | 41.779 | 6.63/1.72 |
| 2008 | 602684 | 90.926 | 38.494 | 42.477 | 2.63/0.67 | 39.822 | 6.69/1.87 |
| 2009 | 605254 | 91.201 | 39.653 | 43.122 | 2.52/0.64 | 39.653 | 7.41/2.06 |
| 2010 | 649146 | 91.813 | 41.439 | 37.742 | 2.49/0.63 | 36.972 | 7.63/2.04 |
| 2011 | 697156 | 92.662 | 43.893 | 35.573 | 2.31/0.59 | 34.426 | 7.81/2.33 |
| 2012 | 742918 | 92.742 | 43.881 | 35.132 | 2.22/0.56 | 30.017 | 8.02/2.24 |
| 2013 | 778083 | 89.836 | 44.982 | 33.030 | 2.09/0.54 | 30.845 | 8.41/2.46 |
| 2014 | 811529 | 92.788 | 43.252 | 30.190 | 2.03/0.52 | 54.835 | 8.58/2.48 |
| 2015 | 861968 | 92.579 | 45.825 | 28.423 | 2.04/0.53 | 41.301 | 8.59/2.58 |
| 2016 | 905368 | 93.001 | 46.390 | 27.061 | 2.02/0.52 | 45.506 | 8.59/2.57 |
| 2017 | 1029556 | 93.049 | 46.039 | 22.534 | 2.01/0.51 | 44.679 | 8.62/2.58 |
| Mean | 89.88 | 41.77 | 36.81 | 2.48/0.63 | 41.01 | 7.56/2.12 | |
| R (%) | 7.01 | 0.97 | 1.04 | −2.91 | −2.51/−2.47 | 0.19 | 2.16/3.1 |
Values were calculated on 100000 people, urban;
O– Obesity; D – Diabetes; MetS - Metabolic Syndrome; GDP – gastroduodenal perforation; GDB – gastroduodenal bleedings; R (%) – Annual increase in %
Characteristics of GDB hospitalized patients with value of comorbidity and risk of recurrence from ulcer bleedings
| Comorbidity Charlson | ||||||
| Score low (0) | 402 (50.6) | 354(88.1) | 48(11.9) | 64(28.6) | 31(48.4) | 33(51.6) |
| Score medium (1–2) | 239 (30.1) | 165(69.0) | 74(31.0) | 95(42.4) | 40(42.1) | 55(57.9) |
| Score high (>2) | 153 (19.3) | 104(68.0) | 49(32.0) | 65(29.0) | 22(33.8) | 43(66.2) |
| Kaplan -Feinstein | ||||||
| Score (0) | 127(16.0) | 87(68.5) | 40(31.5) | 14(6.3) | 7(50.0) | 7(50.0) |
| Score (1) | 250(31.5) | 132(52.8) | 118(47.2) | 36(16.1) | 19(52.8) | 17(47.2) |
| Score (2) | 236(29.7) | 105(44.5) | 131(55.5) | 62(27.7) | 25(40.3) | 37(59.7) |
| Score (3) | 181(22.8) | 80(44.2) | 101(55.8) | 112(50.0) | 37(33.0) | 75(67.0) |
| Anamnesis and treatment | ||||||
| Previous uncomplicated peptic ulcer disease | 127(16.0) | 52(40.9) | 75(59.1) | 59(26.3) | 26(44.1) | 33(55.9) |
| Use of drugs associated with peptic ulcer bleeding | 651(82.0) | 301(46.2) | 350(53.8) | 168(75.0) | 81(18.2) | 87(51.8) |
| Use of antiulcer drugs | 201(25.3) | 102(5.7) | 99(49.3) | 58(25.9) | 32(55.2) | 26(44.8) |
n - number; (%); O – Obesity; D – Diabetes; MetS - Metabolic Syndrome; GDB – gastroduodenal bleedings;